Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, November 7, 2025 — Lunit (KRX:328130.KQ), a...

Article in Nature Communications demonstrates that with 96% sensitivity, AI diagnostic MSIntuit™ CRC can  rule  out  almost  half  of  the  MSS population of colorectal cancer patients unlikely to respond to checkpoint...

Lunit, a firm specializing in cancer diagnostics and therapeutics powered by artificial intelligence (AI), announced the presentation of data from a collaborative study on the use of the Lunit SCOPE IO test to predict immunotherapy treatment...

Akoya Collaborating with Agilent to Catalyze Precision Medicine We recently announced a partnership with Agilent to develop multiplex diagnostic solutions for tissue analysis and to commercialize workflow solutions for these...

Exclusive: combination of drugs causes tumours to vanish in some terminally ill patients, study finds A new cancer treatment can wipe out tumours in terminally ill head and neck cancer patients, scientists have discovered. In a landmark...

NEW YORK – Artificial intelligence company Nucleai and Jefferson Health on Tuesday announced a collaboration to discover histological biomarkers that predict response to immunotherapy. Tel Aviv-based Nucleai will use its ATOM platform to...